Other Guidelines | Page 32 | European Cystic Fibrosis Society (ECFS)

The impact of the first wave of the COVID-19 pandemic on people with cystic fibrosis in New York

CFTR modulator therapy alters sphingolipid profiles in blood from people with cystic fibrosis

Tezacaftor/Ivacaftor in Children ≥6 Years of Age With F508del and Residual Function Changes in CFTR.

Health Changes in People with CF the Year After Having a Child

Use of swelling tests in mini-guts to help determine eligibility for treatment with Trikafta for a CF patient with a rare mutation

Cystic fibrosis outcomes with Tricare Insurance

Measuring CFTR function and relating it to health.

Using safe sampling and DNA tests to diagnose lung infections in children with cystic fibrosis

Worldwide Estimates of Cystic Fibrosis Diagnosis and Treatment Access

Patient and program characteristics which influence screening for bone mineral disease in people with Cystic Fibrosis

first
previous
…
28
29
30
31
32
33
34
35
36
…
next
last